Moxetumomab pasudotox, sold under the brand name Lumoxiti, is an anti-CD22 immunotoxin medication for the treatment of adults with relapsed or refractory...
17 KB (1,438 words) - 04:13, 16 July 2024
developed at the NIH. BL22 was superseded by moxetumomab pasudotox (HA22, CAT-8015). Moxetumomab pasudotox is approved in the EU and USA for treatment...
15 KB (1,761 words) - 19:33, 13 July 2024
moxastine (INN) moxaverine (INN) moxazocine (INN) moxestrol (INN) moxetumomab pasudotox (INN) moxicoumone (INN) moxidectin (INN) moxifloxacin (INN) moxilubant...
6 KB (324 words) - 16:09, 20 March 2022
Bexxar – 2003 – CD20 Mogamulizumab – Poteligeo – August 2018 – CCR4 Moxetumomab pasudotox – Lumoxiti – September 2018 – CD22 Cemiplimab – Libtayo – September...
57 KB (4,072 words) - 11:12, 5 August 2024
patients with HCL-classic or the Japanese variant. HA-22, now renamed moxetumomab pasudotox, is being studied in patients with relapsed hairy cell leukemia...
57 KB (7,246 words) - 00:23, 27 June 2024
immunomodulatory agent, proteasome inhibitor and anti-CD38 antibody Moxetumomab pasudotox Lumoxiti AstraZeneca relapsed or refractory hairy cell leukemia...
41 KB (4,305 words) - 05:27, 17 July 2024
trials included: durvalumab (anti-PD-L1) tremelimumab (anti-CTLA-4) moxetumomab pasudotox (anti-CD22) benralizumab (anti-IL-5R) tralokinumab (anti-IL-13)...
9 KB (800 words) - 00:48, 28 October 2023
respiratory syncytial virus respiratory syncytial virus (prevention) Moxetumomab pasudotox Lumoxiti mab mouse CD22 Y hairy cell leukemia Muromonab-CD3 Orthoclone...
135 KB (4,054 words) - 22:35, 2 July 2024
Loncastuximab tesirine Mirvetuximab soravtansine Mogamulizumab Moxetumomab pasudotox Naxitamab Necitumumab Nivolumab Olaratumab Oportuzumab monatox Pembrolizumab...
12 KB (758 words) - 23:46, 14 March 2024
Loncastuximab tesirine Mirvetuximab soravtansine Mogamulizumab Moxetumomab pasudotox Naxitamab Necitumumab Nivolumab Olaratumab Oportuzumab monatox Pembrolizumab...
12 KB (760 words) - 03:40, 23 July 2024
tested in humans with various forms of cancer. One of these, HA22 or Moxetumomab pasudotox (Moxe), targets CD22 on B cell malignancies; it has produced many...
13 KB (1,810 words) - 05:43, 2 February 2023
tiuxetan Igovomab Lilotomab Minretumomab Mitumomab Nacolomab tafenatox Moxetumomab pasudotox Naptumomab estafenatox Oregovomab Pemtumomab† Racotumomab Satumomab...
5 KB (368 words) - 23:51, 17 July 2024
Ofatumumab L01FA03 Obinutuzumab L01FB01 Inotuzumab ozogamicin L01FB02 Moxetumomab pasudotox L01FC01 Daratumumab L01FC02 Isatuximab L01FD01 Trastuzumab L01FD02...
12 KB (877 words) - 15:36, 25 January 2024
targeting IL-13 for adults with moderate-to-severe atopic dermatitis". Moxetumomab pasudotox (CAT-3888) – CAT-3888 (formerly GCR-3888 and BL22) and CAT-8015...
91 KB (8,494 words) - 15:09, 10 August 2024
sulfate liposomal injections (Marqibo®), a pediatric phase I trial of moxetumomab pasudotox, (an anti-CD22 targeted immunotoxin based therapy), and a pilot...
12 KB (1,198 words) - 16:53, 14 May 2024
remissions in a phase I trial for leukemia. CAT-3888 was succeeded by moxetumomab pasudotox (CAT-8015, HA22), an anti-CD22 immunotoxin comprising a modified...
9 KB (848 words) - 02:25, 10 March 2024
tiuxetan Igovomab Lilotomab Minretumomab Mitumomab Nacolomab tafenatox Moxetumomab pasudotox Naptumomab estafenatox Oregovomab Pemtumomab† Racotumomab Satumomab...
3 KB (129 words) - 01:04, 19 July 2023
tiuxetan Igovomab Lilotomab Minretumomab Mitumomab Nacolomab tafenatox Moxetumomab pasudotox Naptumomab estafenatox Oregovomab Pemtumomab† Racotumomab Satumomab...
4 KB (241 words) - 13:42, 14 July 2024